Carbapenem-Resistant Enterobacteriaceae

Alina Iovleva, Yohei Doi

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) have emerged as a major threat. Commonly used antibiotics are generally inactive against CRE. Therefore, timely detection of CRE is of paramount importance. Among CRE, those producing carbapenem-hydrolyzing β-lactamase enzymes (carbapenemase-producing Enterobacteriaceae) are particularly of concern because they tend to spread, and treatment is difficult. The carbapenemase groups most commonly encountered include KPC, NDM, and OXA-48. Treatment options are limited and include combinations of polymyxins, tigecycline, aminoglycosides, or carbapenems; newer agents with activity against CRE and better safety profiles are becoming available and will likely emerge as the preferred therapy.

Original languageEnglish
Pages (from-to)303-315
Number of pages13
JournalClinics in Laboratory Medicine
Volume37
Issue number2
DOIs
Publication statusPublished - 06-2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Carbapenem-Resistant Enterobacteriaceae'. Together they form a unique fingerprint.

  • Cite this